Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2Unknown 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Stomach Neoplasms 12Neoplasms 8Breast Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasm Metastasis 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Osteosarcoma 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Advanced Solid Tumor 2Advanced Gastric Cancer 2Thyroid Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Quality of Life 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Amifostine 12Cisplatin 10Radiotherapy 8Etoposide 8Cyclophosphamide 5Paclitaxel 4Filgrastim 4Gemcitabine 3Cytarabine 3Carboplatin 3denileukin diftitox 2apatinib 2Vincristine 2Pyridoxine 2Irinotecan 2Ifosfamide 2Fibroblast Growth Factor 7 2Epoetin Alfa 2Doxorubicin 2Dexamethasone 2Chemotherapy, Adjuvant 2Bleomycin 2uridine triacetate 1sargramostim 1peginterferon alfa-2b 1pegfilgrastim 1pegaspargase 1eribulin 1camrelizumab 1Vitamin E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Drug-Related Side Effects and Adverse Reactions × apatinib × Clear all
NCT04690231 2022-03-15

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Peking University People's Hospital

Phase NA Completed
79 enrolled
Sarcoma

Osteosarcoma, Drug-Related Side Effects and Adverse Reactions

NCT04260113 2021-01-05

AIAC

Peking University People's Hospital

Phase NA Completed
40 enrolled
Sarcoma

Chondrosarcoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡